Key Takeaways
- Foundayo (orforglipron) starts at 0.8mg once daily and steps up every 30+ days through 2.5mg, 5.5mg, 9mg, 14.5mg, and up to a 17.2mg maintenance dose.
- Unlike peptide GLP-1 tablets, Foundayo can be swallowed whole at any time of day, with or without food and with as much water as needed.
- Gradual 30-day dose escalation helps minimize common gastrointestinal side effects (experienced by 60–69% of trial participants) while sustaining weight loss.
For many patients, an oral GLP-1 weight loss medication like Foundayo (orforglipron) is preferred to self-administered injections. This once-daily oral treatment is prescribed alongside a reduced-calorie diet and increased physical activity to help adults living with obesity lose excess weight. However, when and how you take Foundayo is essential for it to work effectively (1).
What dose of Foundayo (orforglipron) is right for me?
You will start Foundayo on the lowest 0.8mg dose to reduce the risk of gastrointestinal side effects. Like other GLP-1 receptor agonists, Foundayo supports weight management by regulating appetite signals and slowing gastric emptying. While this helps reduce overall calorie intake, digestive side effects such as nausea, vomiting, diarrhea, and constipation are common during early treatment.
Starting on a low dose and gradually titrating gives your body time to adapt, making treatment more comfortable and improving long-term adherence (2). Your weight loss journey is personal — while there is a standard dose titration schedule, you do not have to rush to the maximum strength if a lower maintenance dose delivers steady results with minimal side effects (3).
What is the Foundayo (orforglipron) dosing schedule?
The confirmed Patient Information Leaflet (PIL) follows a spaced titration schedule of 6 strengths taken at least 30 days apart (4):
| Weeks | Daily Strength | Clinical Titration Guidance |
|---|---|---|
| Weeks 1–4 | 0.8mg once daily | Starting introductory dose taken for at least 30 days so your digestive system adapts. |
| Weeks 5–8 | 2.5mg once daily | Step up if tolerating 0.8mg well. Side effects may briefly increase after stepping up. |
| Weeks 9–12 | 5.5mg once daily | Continue at 5.5mg if losing weight steadily, or step up after 30+ days if well tolerated. |
| Weeks 13–16 | 9mg once daily | Mid-to-high maintenance option; remain here if achieving consistent progress or escalate if needed. |
| Weeks 17–20 | 14.5mg once daily | Near the top of the titration ladder for patients needing stronger appetite regulation. |
| Weeks 21+ | 17.2mg once daily | Maximum licensed maintenance dose. Do not exceed 17.2mg daily. |
Beyond 2.5mg, further increases are guided by your clinical response and tolerability rather than a rigid calendar. There must always be a minimum of 30 days between each dose escalation (4,5).
Do side effects get worse when you increase your Foundayo dose?
Mild-to-moderate digestive symptoms are common across GLP-1 therapies. In phase 3 clinical trials, 60% to 69% of participants experienced gastrointestinal events, depending on tablet strength (6). If symptoms have not settled before your next scheduled step-up, your clinician may recommend:
- Delaying your next dose increase beyond 30 days
- Remaining on your current strength as your maintenance dose
- Stepping back temporarily to the previous well-tolerated strength
What time of day is best to take Foundayo?
There is no mandatory time of day to take Foundayo. Because orforglipron is a non-peptide small-molecule GLP-1 agonist, the Patient Information Leaflet confirms you can take it at any time of day, with or without food (5). Choosing the same time each morning or evening helps build a reliable daily habit.
How to take Foundayo (orforglipron) daily
Foundayo should be taken once daily and swallowed whole — never break, crush, or chew the film-coated tablet. Unlike oral semaglutide tablets, you can swallow Foundayo with as much water as you like and alongside meals (5).
Consistent daily dosing keeps blood levels steady. If you miss a week or more of treatment, consult your prescribing clinician before restarting, as re-titration from a lower dose may be advised to prevent rebound nausea (4,5).
- 30 days is a minimum, not a race to the top strength.
- The highest dose is not automatically the best dose if you are already losing weight comfortably at a moderate strength.
- Balanced nutrition, protein intake, and resistance activity remain essential alongside oral GLP-1 treatment.
References
- Eli Lilly. Foundayo (orforglipron) Once-Daily Oral GLP-1 RA Overview. Accessed October 2026.
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025;393(18):1796–1806.
- Lilly Medical. Approved Dosing for Foundayo (Orforglipron) for Weight Management. 2026.
- electronic Medicines Compendium (emc). Foundayo 0.8mg–17.2mg Film-Coated Tablets Patient Information Leaflet. August 2026.
- electronic Medicines Compendium (emc). Foundayo Summary of Product Characteristics (SmPC). 2026.
- Lilly Medical. Incidence of Gastrointestinal Adverse Events with Foundayo (Orforglipron). 2026.
Your personalizedweight care plan
Clinician-prescribed GLP-1 & metabolic care, 100% online.